Table 2.
Patient characteristics (N = 100)
| Variable | FSGS (n = 19) | MN (n = 16) | IgAN (n = 27) | LN (n = 18) | AAV (n = 18) | MPGN (n = 2) |
|---|---|---|---|---|---|---|
| Age (yr) | 54 ± 19 | 55 ± 13 | 41 ± 15 | 36 ± 11 | 64 ± 12 | 51 ± 15 |
| Female sex, % | 37 | 31 | 33 | 61 | 22 | 50 |
| Total duration of follow-up (mo) | 22 (13–41) | 42 (19–63) | 22 (13–54) | 40 (20–71) | 36 (24–45) | 100 (95–106) |
| Active periods with remission (n) | 16 | 12 | 12 | 13 | 13 | 4 |
| Initial eGFR (ml/min per 1.73 m2) | 44 ± 28 | 61 ± 34 | 66 ± 20 | 74 ± 40 | 22 ± 14 | 29 ± 7 |
| Initial blood pressure (mm Hg) | 133/80 ± 19/10 | 141/82 ± 16/12 | 131/82 ± 15/10 | 131/82 ± 18/12 | 144/81 ± 20/14 | 110/71 ± 8/9 |
| Antihypertensive medication, n, % RASB | 3 (2–3), 94 | 2 (1–2), 83 | 1 (1–3), 91 | 2 (0–3), 36 | 2 (1–3), 60 | 3 (1–3), 75 |
| Initial proteinuria (g/g of creatinine) | 8.3 (4.2–10.1) | 9.4 (7.2–11.8) | 2.5 (1.2–4.1) | 6.8 (3.0–10.6) | 2.3 (1.2–5.8) | 2.2 (1.6–3.3) |
| Use of immunosuppression (%) | 81 | 75 | 92 | 100 | 100 | 100 |
| Duration (mo) | 10 (3–13) | 8 (6–16) | 9 (4–13) | 14 (10–20) | 5 (4–6) | 36 (17–60) |
| Rate of renal function changea | –12.6 ± 22.0 | –2.1 ± 21.2 | –8.7 ± 16.0 | +2.0 ± 10.5 | +38.4 ± 23.5 | –2.4 ± 1.3 |
| Active periods without remission (n) | 5 | 3 | 17 | 0 | 0 | 0 |
| Initial eGFR (ml/min per 1.73 m2) | 40 ± 7 | 74 ± 25 | 59 ± 37 | — | — | — |
| Initial blood pressure (mm Hg) | 146/81 ± 12/13 | 110/72 ± 14/2 | 129/82 ± 15/9 | — | — | — |
| Antihypertensive medication, n, % RASB | 3 (1–4), 80 | 2 (2–2), 100 | 2 (1–3), 100 | — | — | — |
| Initial proteinuria (g/g creatinine) | 5.5 (4.4–7.9) | 10.5 (7.3–12.0) | 1.4 (1.1–3.0) | — | — | — |
| Use of immunosuppression (%) | 40 | 67 | 53 | — | — | — |
| Duration (mo) | 16 (3–22) | 7 (6–18) | 17 (7–38) | — | — | — |
| Rate of renal function changea | –15.1 ± 17.9 | –7.8 ± 12.1 | –2.6 ± 5.7 | — | — | — |
| Inactive periods (n) | 17 | 13 | 12 | 18 | 18 | 4 |
| Initial eGFR (ml/min per 1.73 m2) | 33 ± 18 | 67 ± 36 | 66 ± 32 | 77 ± 38 | 36 ± 19 | 22 ± 5 |
| Initial blood pressure (mm Hg) | 130/74 ± 19/11 | 127/76 ± 20/11 | 136/81 ± 11/7 | 121/78 ± 12/11 | 137/80 ± 20/11 | 123/81 ±11/7 |
| Antihypertensive medication, n, % RASB | 2 (2–3), 100 | 2 (2–4), 92 | 2 (1–3), 82 | 2 (1–4), 65 | 2 (1–3), 50 | 3 (1–3), 75 |
| Initial proteinuria (g/g creatinine) | 1.8 (1.3–2.6) | 1.6 (0.4–2.4) | 0.6 (0.5–0.8) | 0.5 (0.2–1.0) | 0.9 (0.3–1.6) | 0.8 (0.5–0.9) |
| Use of immunosuppression (%) | 47 | 23 | 58 | 78 | 100 | 100 |
| Duration (mo) | 11 (6–22) | 27 (19–47) | 14 (5–26) | 24 (18–47) | 28 (19–37) | 11 (3–23) |
| Rate of renal function changea | +0.5 ± 5.3 | –0.3 ± 5.6 | +3.6 ± 14.0 | +0.6 ± 4.5 | +2.4 ± 5.4 | –5.3 ± 5.0 |
| Relapse (%) | 41 | 8 | 25 | 11 | 6 | 50 |
AAV, anti-neutrophil cytoplasmic autoantibody–associated vasculitis; eGFR, estimated glomerular filtration rate; FSGS, focal and segmental glomerulosclerosis; IgAN, IgA nephropathy; LN, lupus nephritis; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis; RASB, renin-angiotensin system blockade.
a
In milliliters per minute per 1.73 m2 per yr.